Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study

References

• Nguyen TV, Damiani G, Orenstein LAV, et al. Hidradenitis Suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2020 May 27;35(1):50–61. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020 Mar 12;6(1):18.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb). 2020 Feb;10(1):63–71.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91–101.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619–644.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009–1017.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011 May;91(3):328–332.
   PubMed Web of Science ®Google Scholar
• Mac Mahon J, Kirthi S, Byrne N, et al. An update on health-related quality of life and patient-reported outcomes in Hidradenitis Suppurativa. Patient Relat Outcome Meas. 2020;11:21–26.
   PubMed Web of Science ®Google Scholar
• Theut Riis P, Thorlacius L, Knudsen List E, et al. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br J Dermatol. 2017 Apr;176(4):1083–1085. .
   PubMed Web of Science ®Google Scholar
• Tzellos T, Yang H, Mu F, et al. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019 Jul;181(1):147–154. .
   PubMed Web of Science ®Google Scholar
• Van Straalen KR, Prens LM, Hylkema TH, et al. Impact of Hidradenitis Suppurativa on work productivity and associated risk factors. J Am Acad Dermatol. 2020. [Epub ahead of print] Aug 4. https://doi.org/10.1016/j.jaad.2020.07.115
   Google Scholar
• Gergely LH, Gáspár K, Brodszky V, et al. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020 Jul 2;34(11):2584–2592. .
   PubMed Web of Science ®Google Scholar
• Segel JE. Cost of illness studies – A primer: RTI International. US: RTI-UNC Center of Excellence in Health Promotion Economics. North Carolina; 2006 January.
   Google Scholar
• Byford S, Raftery J. Perspectives in economic evaluation. BMJ (Clin Res Ed). 1998;316(7143):1529–1530.
   PubMed Web of Science ®Google Scholar
• Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol. 2017 Apr;176(4):1048–1055. .
   PubMed Web of Science ®Google Scholar
• Marvel J, Vlahiotis A, Sainski-Nguyen A, et al. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. 2019 Sep 30;9(9):e030579.
   PubMed Web of Science ®Google Scholar
• Patel KR, Rastogi S, Singam V, et al. Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: a cross-sectional analysis of the National Inpatient Sample. Br J Dermatol. 2019 Aug;181(2):275–281. .
   PubMed Web of Science ®Google Scholar
• Yang EJ, Beck KM, Bhutani T, et al. Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. J DermatolTreat. 2019 Aug;30(5):519–521. .
   Google Scholar
• Kirby JS, Miller JJ, Adams DR, et al. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014 Sep;150(9):937–944.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Guerin A, Kaminsky M, et al. What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis. J Med Econ. 2016 Jul;19(7):710–717.
   PubMed Web of Science ®Google Scholar
• Mehdizadeh A, Rosella L, Alavi A, et al. A Canadian population-based cohort to the study cost and burden of surgically resected Hidradenitis Suppurativa. J Cutan Med Surg. 2018 May;22(3):312–317.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Beretzky Z, Baji P, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Econ. 2019 Jun;20(Suppl 1):155–172.
   PubMedGoogle Scholar
• Brodszky V, Tamasi B, Hajdu K, et al. Disease burden of patients with pemphigus from a societal perspective. Expert Rev Pharmacoecon Outcomes Res. 2020;28:1–9.
   Google Scholar
• Bató A, Brodszky V, Gergely LH, et al. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res. 2021. [Epub ahead of print]. DOI:https://doi.org/10.1007/s11136-020-02732-x.
   Google Scholar
• Hurley H. Dermatologic surgery, principles and practice. In: Randall K. Roenigk and Harvey H. Roenigk, Jr, editors. Dermatologic surgery, principles and practice Marcel Dekker. New York; 1989. p. 729–739.
   Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012 Dec 18;157(12):846–855.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009 Oct;161(4):831–839. .
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005 Oct;125(4):659–664. .
   PubMed Web of Science ®Google Scholar
• Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev. 2006 Apr;63(2):217–235.
   PubMed Web of Science ®Google Scholar
• National Health Insurance Fund Administration Management. Hungary: statistical year book 2018. Available from: http://site.oep.hu/statisztika/2018/html/indexeng.html cited 2020 Mar 10.
   Google Scholar
• National Institute of Health Insurance Fund Management (2019) Diagnosis-related groups (DRG) classification scheme 5.0. Available from: http://www.neak.gov.hu//data/cms1025530/10_2012_NEFMI_fekvo_2020.02.01.docx cited 2020 May 9.
   Google Scholar
• National Institute of Health Insurance Fund Management (2019) International classification of procedures in medicine codes. Available from: http://finanszirozas.neak.gov.hu/szabalykonyv/index.asp?mid=1 cited 2020 May 9.
   Google Scholar
• Government order No. 3/1999. (III. 3.) about financing healthcare services through the National Institute of Health Insurance Fund Management in Hungary. Available from: https://net.jogtar.hu/jogszabaly?docid=99900043.kor cited 2020 May 16.
   Google Scholar
• National Institute of Health Insurance Fund Management (2019). Official price list for the reimbursement of medical devices. Available from: http://sejk.oep.hu/ cited 2020 May 9.
   Google Scholar
• Koopmanschap MA, Van Exel JN, Van Den Berg B, et al. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269–280. .
   PubMed Web of Science ®Google Scholar
• Hungarian Central Statistical Office (KSH): Average net earnings of full-time employees without benefits by location of the employer’s head office (2019). Available from: http://www.ksh.hu/docs/eng/xstadat/xstadat_infra/e_qli030b.html cited 2020 Mar 14.
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):1–7.
   PubMed Web of Science ®Google Scholar
• Hungarian Central Statistical Office (KSH): Monthly gross earnings of full-time employees by economic branches – national economy total (2019). Available from: https://www.ksh.hu/docs/eng/xstadat/xstadat_infra/e_qli007a.html cited 2020 Feb 4.
   Google Scholar
• Desgagné A, Castilloux AM, Angers JF, et al. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998 May;13(5 Pt 1):487–497. .
   PubMed Web of Science ®Google Scholar
• Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000 Dec 15;19(23):3219–3236.
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001 Jul;20(4):461–494.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Burudpakdee C, Gala S, et al. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):685–705. .
   PubMed Web of Science ®Google Scholar
• Politiek K, Oosterhaven JA, Vermeulen KM, et al. Systematic review of cost-of-illness studies in hand eczema. Contact Dermatitis. 2016 Aug;75(2):67–76. .
   PubMed Web of Science ®Google Scholar
• Murota H, Inoue S, Yoshida K, et al. Cost of illness study for adult atopic dermatitis in Japan: a cross-sectional Web-based survey. J Dermatol. 2020 May 7;7(7):689–698.
   Google Scholar
• Krensel M, Schafer I, Augustin M. Cost-of-illness of melanoma in Europe - a systematic review of the published literature. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):504–510.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Carroll C, Stevens JW, et al. Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017 Aug;35(8):805–815.
   PubMed Web of Science ®Google Scholar
• Argyropoulou M, Kanni T, Kyprianou M, et al. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol. 2019 May;180(5):1161–1168.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Burton T. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics? Br J Dermatol. 2017 Feb;176(2):281–282.
   PubMed Web of Science ®Google Scholar
• Willems D, Charokopou M, Evers S, et al. Early health economic modelling for a treatment candidate in hidradenitis suppurativa. J Med Econ. 2020 Oct;21:1. [Epub ahead of print].
   Google Scholar
• Balogh O, Brodszky V, Gulacsi L, et al. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ. 2014 May;15(Suppl 1):S101–9. .
   PubMedGoogle Scholar
• Jungen D, Augustin M, Langenbruch A, et al. Cost-of-illness of psoriasis – results of a German cross-sectional study. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):174–180. .
   PubMed Web of Science ®Google Scholar
• Polistena B, Calzavara-Pinton P, Altomare G, et al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2411–2416. .
   PubMed Web of Science ®Google Scholar
• McKenzie SA, Lev-Tov HA, Shi VY, et al. Clinical pearls for managing hidradenitis suppurativa patients of low socioeconomic status. Dermatology. 2020;236(5):439–444. .
   PubMed Web of Science ®Google Scholar
• Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Annu Rev Sociol. 2010 Aug;36(1):349–370.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010 Apr;62(4):706–708. . 708.e1.
   PubMed Web of Science ®Google Scholar
• Wlodarek K, Glowaczewska A, Matusiak L, et al. Psychosocial burden of Hidradenitis Suppurativa patients’ partners. J Eur Acad Dermatol Venereol. 2020 Jan 31;34(8):1822–1827.
   PubMed Web of Science ®Google Scholar
• Chen WT, Chi CC. Association of Hidradenitis Suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2019 Jul 10;155(9):1022–1027.
   PubMed Web of Science ®Google Scholar
• Phan K, Tatian A, Woods J, et al. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. Int J Dermatol. 2020 Feb;59(2):221–228.
   PubMed Web of Science ®Google Scholar
• Ramos-Rodriguez AJ, Timerman D, Khan A, et al. The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. Int J Dermatol. 2018 May;57(5):547–552.
   PubMed Web of Science ®Google Scholar
• Kigozi J, Jowett S, Lewis M, et al. The estimation and inclusion of presenteeism costs in applied economic evaluation: a Systematic Review. Value Health. 2017 Mar;20(3):496–506.
   PubMed Web of Science ®Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009 Jun;12(4):409–418.
   PubMed Web of Science ®Google Scholar
• Flood KS, Porter ML, Kimball AB. Biologic treatment for Hidradenitis Suppurativa. Am J Clin Dermatol. 2019 Oct;20(5):625–638.
   PubMed Web of Science ®Google Scholar